FilingReader Intelligence
Shanghai Shyndec subsidiary wins ketamine hydrochloride approval
August 7, 2025 at 08:49 AM UTC•By FilingReader AI
Shanghai Shyndec Pharmaceutical's subsidiary Sinopharm Industrial has received approval to market Ketamine Hydrochloride API, a controlled pharmaceutical raw material.
The company invested approximately RMB 75.2m in research and development for the project, expanding its specialized API product portfolio.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600420•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Shyndec Pharmaceutical publishes news
Free account required • Unsubscribe anytime